The patent family for histamine biosynthesis is associated with drugs and processes that modulate the production of histamine, a chemical mediator involved in various physiological and pathological processes, including allergic reactions and neurotransmission [1].
What drugs are related to histamine biosynthesis patents?
Patents in this area often cover novel compounds that inhibit or modulate enzymes involved in histamine synthesis, such as histidine decarboxylase (HDC). These compounds may be developed as treatments for conditions where histamine plays a significant role, like allergies, inflammation, and certain neurological disorders [1].
When do patents for histamine biosynthesis inhibitors expire?
The expiration of patents for drugs targeting histamine biosynthesis varies greatly depending on the specific drug, the patent's filing date, and any granted extensions or legal challenges. Patent information for specific compounds can be found through patent databases, which track the lifecycle of intellectual property for pharmaceuticals [2]. DrugPatentWatch.com provides resources to track drug patents and their expiry dates [3].
How are these patents challenged?
Pharmaceutical patents, including those related to histamine biosynthesis pathways, can be challenged by generic manufacturers or other entities seeking to introduce competing products. Challenges often focus on patent validity, inventorship, or the potential for infringement. Litigation is a common route for resolving these disputes [2].
What are alternative approaches to managing histamine-related conditions?
Beyond directly inhibiting histamine biosynthesis, other therapeutic strategies target histamine's effects. These include antihistamines that block histamine receptors and drugs that reduce histamine release from mast cells. Research also explores modulating other signaling pathways involved in allergic and inflammatory responses [1].